Cerevel Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2018-01-01

Employees: -

Market Cap: $8.1B

Website: https://www.cerevel.com/

Clinical Trials

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Phase 1

Recruiting

Conditions: Alzheimer's Disease Dementia
Healthy Participants

Interventions: Drug: Emraclidine
Drug: Placebo

First Posted Date: 2022-12-09

Last Posted Date: 2024-12-13

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 78

Registration Number: NCT05644977

Locations: 🇺🇸
San Diego, California, San Diego, California, United States
🇺🇸
Cypress, California, Cypress, California, United States
🇺🇸
Hialeah, Florida, Hialeah, Florida, United States

and more 8 locations

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: Tavapadon

First Posted Date: 2022-11-09

Last Posted Date: 2024-02-08

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 25

Registration Number: NCT05610189

Locations: 🇺🇸
South Miami, Florida, South Miami, Florida, United States
🇺🇸
Hollywood, Florida, Hollywood, Florida, United States
🇺🇸
Farmington Hills, Michigan, Farmington Hills, Michigan, United States

and more 3 locations

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: Tavapadon
Drug: Carbamazepine

First Posted Date: 2022-10-17

Last Posted Date: 2023-04-20

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 16

Registration Number: NCT05581823

Locations: 🇺🇸
Madison, Wisconsin, Madison, Wisconsin, United States

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Phase 1

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: CVL-354
Drug: [11C]-LY2795050
Drug: [11C]-carfentanil

First Posted Date: 2022-09-21

Last Posted Date: 2024-08-26

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 19

Registration Number: NCT05547542

Locations: 🇺🇸
New Haven, Connecticut, New Haven, Connecticut, United States
🇺🇸
Yale PET Center, New Haven, Connecticut, United States

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Phase 2

Recruiting

Conditions: Schizophrenia

Interventions: Drug: CVL-231 30 mg

First Posted Date: 2022-07-05

Last Posted Date: 2024-12-10

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 850

Registration Number: NCT05443724

Locations: 🇺🇸
Oklahoma City, Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Phoenix, Arizona, Phoenix, Arizona, United States
🇺🇸
Bentonville, Arkansas, Bentonville, Arkansas, United States

and more 73 locations

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Tavapadon

First Posted Date: 2022-06-03

Last Posted Date: 2023-05-30

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 32

Registration Number: NCT05404529

Locations: 🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
Orlando, Florida, Orlando, Florida, United States
🇺🇸
San Antonio, Texas, San Antonio, Texas, United States

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Tavapadon

First Posted Date: 2022-06-03

Last Posted Date: 2024-04-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 14

Registration Number: NCT05404542

Locations: 🇺🇸
Jacksonville, Florida, Jacksonville, Florida, United States
🇺🇸
Tampa, Florida, Tampa, Florida, United States
🇺🇸
Miami, Florida, Miami, Florida, United States

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Phase 1

Completed

Conditions: Blood Pressure
Schizophrenia

Interventions: Drug: CVL-231

First Posted Date: 2022-02-18

Last Posted Date: 2022-12-14

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 151

Registration Number: NCT05245539

Locations: 🇺🇸
Uptown Research Institute LLC, Chicago, Illinois, United States
🇺🇸
Hassman Research Institute - Apex - PPDS, Marlton, New Jersey, United States
🇺🇸
Woodland International Research Group LLC - ERG - PPDS, Little Rock, Arkansas, United States

and more 5 locations

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: CVL-231 10 mg
Drug: Required CVL-231 30 mg
Drug: Placebo

First Posted Date: 2022-02-07

Last Posted Date: 2024-12-20

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 385

Registration Number: NCT05227690

Locations: 🇺🇸
Oakland Park, Florida, Oakland Park, Florida, United States
🇺🇸
DeSoto, Texas, DeSoto, Texas, United States
🇺🇸
Richardson, Texas, Richardson, Texas, United States

and more 22 locations

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Required CVL-231 30 mg
Drug: CVL-231 15 mg
Drug: Placebo

First Posted Date: 2022-02-07

Last Posted Date: 2024-12-20

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 391

Registration Number: NCT05227703

Locations: 🇭🇺
Kalocsa, Bács-Kiskun, Kalocsa, Bács-Kiskun, Hungary
🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
Bellflower, California, Bellflower, California, United States

and more 22 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy